A detailed history of Fayez Sarofim & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Fayez Sarofim & CO holds 2,052,894 shares of ABBV stock, worth $350 Million. This represents 1.05% of its overall portfolio holdings.

Number of Shares
2,052,894
Previous 2,028,833 1.19%
Holding current value
$350 Million
Previous $348 Million 16.5%
% of portfolio
1.05%
Previous 0.95%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $3.94 Million - $4.8 Million
24,061 Added 1.19%
2,052,894 $405 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $16.1 Million - $18.7 Million
103,709 Added 5.39%
2,028,833 $348 Million
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $1.3 Million - $1.48 Million
-8,122 Reduced 0.42%
1,925,124 $351 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $8.97 Million - $10.1 Million
-65,209 Reduced 3.26%
1,933,246 $300 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $11.7 Million - $13.5 Million
87,539 Added 4.58%
1,998,455 $298 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $21.6 Million - $26.9 Million
-163,187 Reduced 7.87%
1,910,916 $257 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $7.72 Million - $8.89 Million
53,400 Added 2.64%
2,074,103 $331 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $25.1 Million - $30.1 Million
-181,557 Reduced 8.24%
2,020,703 $327 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $632,800 - $725,779
-4,715 Reduced 0.21%
2,202,260 $296 Million
Q2 2022

Aug 12, 2022

SELL
$137.62 - $174.96 $1.23 Million - $1.57 Million
-8,973 Reduced 0.4%
2,206,975 $338 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $1.07 Million - $1.33 Million
8,113 Added 0.37%
2,215,948 $359 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $1.47 Million - $1.86 Million
13,674 Added 0.62%
2,207,835 $299 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $22.9 Million - $26 Million
-215,203 Reduced 8.93%
2,194,161 $237 Million
Q2 2021

Aug 13, 2021

SELL
$105.21 - $117.21 $55.9 Million - $62.3 Million
-531,664 Reduced 18.08%
2,409,364 $271 Million
Q1 2021

May 13, 2021

SELL
$102.3 - $112.62 $12.2 Million - $13.4 Million
-118,969 Reduced 3.89%
2,941,028 $318 Million
Q4 2020

Feb 11, 2021

SELL
$80.49 - $108.67 $9.74 Million - $13.1 Million
-121,006 Reduced 3.8%
3,059,997 $328 Million
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $21.5 Million - $25.2 Million
-250,243 Reduced 7.29%
3,181,003 $279 Million
Q2 2020

Aug 11, 2020

BUY
$73.37 - $98.18 $28.2 Million - $37.8 Million
384,878 Added 12.63%
3,431,246 $337 Million
Q1 2020

May 12, 2020

SELL
$64.5 - $97.79 $9.47 Million - $14.4 Million
-146,775 Reduced 4.6%
3,046,368 $232 Million
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $6.88 Million - $8.61 Million
-95,360 Reduced 2.9%
3,193,143 $283 Million
Q3 2019

Nov 13, 2019

SELL
$62.98 - $75.72 $3.91 Million - $4.71 Million
-62,150 Reduced 1.85%
3,288,503 $249 Million
Q2 2019

Aug 09, 2019

SELL
$65.7 - $83.98 $3.5 Million - $4.47 Million
-53,203 Reduced 1.56%
3,350,653 $244 Million
Q1 2019

May 14, 2019

SELL
$77.14 - $90.79 $2.46 Million - $2.9 Million
-31,924 Reduced 0.93%
3,403,856 $274 Million
Q4 2018

Feb 13, 2019

SELL
$77.85 - $96.01 $3.31 Million - $4.08 Million
-42,483 Reduced 1.22%
3,435,780 $317 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $5.03 Million - $5.59 Million
-56,550 Reduced 1.6%
3,478,263 $329 Million
Q2 2018

Aug 14, 2018

SELL
$89.78 - $106.23 $7.89 Million - $9.33 Million
-87,843 Reduced 2.42%
3,534,813 $328 Million
Q1 2018

May 10, 2018

BUY
$92.01 - $123.21 $4.17 Million - $5.58 Million
45,297 Added 1.27%
3,622,656 $343 Million
Q4 2017

Feb 13, 2018

SELL
$89.56 - $98.21 $11.6 Million - $12.7 Million
-129,544 Reduced 3.49%
3,577,359 $346 Million
Q3 2017

Nov 08, 2017

BUY
$69.85 - $89.22 $259 Million - $331 Million
3,706,903
3,706,903 $329 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Fayez Sarofim & CO Portfolio

Follow Fayez Sarofim & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.